Skip to main content
. Author manuscript; available in PMC: 2015 Sep 3.
Published in final edited form as: Thorax. 2014 Jan 24;69(6):565–573. doi: 10.1136/thoraxjnl-2013-204605

Fig 3. Five weekly 1018 ISS treatments are required for durable suppression of allergen-induced Th2 responses in the airways.

Fig 3

Tx protocol 2 with 1, 3, 5, or 8 weekly RW+1018 ISS treatments followed by 4 weekly RW exposures, compared to continual RW exposures. BALF cytokines and eosinophils depicted (mean ± SEM, 5 mice/group). **P <0.01 and ***P<0.001, compared to RW. 1 representative experiment of 2 shown.